Catawba Capital Management Va buys $5,471,704 stake in Zimmer Biomet Holdings Inc (ZBH)

Zimmer Biomet Holdings Inc (ZBH) : Catawba Capital Management Va scooped up 1,246 additional shares in Zimmer Biomet Holdings Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 19, 2016. The investment management firm now holds a total of 43,258 shares of Zimmer Biomet Holdings Inc which is valued at $5,471,704.Zimmer Biomet Holdings Inc makes up approximately 1.29% of Catawba Capital Management Va’s portfolio.

Other Hedge Funds, Including , Acadian Asset Management added ZBH to its portfolio by purchasing 57 company shares during the most recent quarter which is valued at $7,210. Iab Financial Bank sold out all of its stake in ZBH during the most recent quarter. The investment firm sold 1,000 shares of ZBH which is valued $126,490.First Manhattan Co reduced its stake in ZBH by selling 36,151 shares or 1.4% in the most recent quarter. The Hedge Fund company now holds 2,542,607 shares of ZBH which is valued at $317,368,206. Zimmer Biomet Holdings Inc makes up approx 1.90% of First Manhattan Co’s portfolio.Dnb Asset Management As reduced its stake in ZBH by selling 44,600 shares or 73.83% in the most recent quarter. The Hedge Fund company now holds 15,808 shares of ZBH which is valued at $1,974,261. Zimmer Biomet Holdings Inc makes up approx 0.04% of Dnb Asset Management As’s portfolio.

Zimmer Biomet Holdings Inc opened for trading at $125.33 and hit $126.66 on the upside on Wednesday, eventually ending the session at $126.49, with a gain of 1.58% or 1.97 points. The heightened volatility saw the trading volume jump to 8,45,725 shares. Company has a market cap of $25,202 M.

On the company’s financial health, Zimmer Biomet Holdings Inc reported $2.00 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $1.93. The company had revenue of $1904.00 million for the quarter, compared to analysts expectations of $1878.31 million. The company’s revenue was up 67.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.54 EPS.

Many Wall Street Analysts have commented on Zimmer Biomet Holdings Inc. Company shares were Reiterated by Needham on Jul 18, 2016 to “Buy”, Firm has raised the Price Target to $ 143 from a previous price target of $134 .Zimmer Biomet Holdings Inc was Initiated by Guggenheim to “Neutral” on Jun 9, 2016. Company shares were Reiterated by Barclays on Apr 29, 2016 to “Overweight”, Firm has raised the Price Target to $ 135 from a previous price target of $130 .

Zimmer Biomet Holdings Inc. formerly Zimmer Holdings Inc. is a musculoskeletal healthcare company. The Company designs manufactures and markets orthopedic reconstructive products; sports medicine biologics extremities and trauma products; spine bone healing craniomaxillofacial and thoracic products; dental implants and related surgical products. The Company manages its operations through three geographic segments: the Americas comprising principally of the United States and includes other North Central and South American markets; Europe comprising principally of Europe and includes the Middle East and African markets; and Asia Pacific comprising primarily of Japan and includes other Asian and Pacific markets. The Company markets and sells products through three channels: direct to healthcare institutions such as hospitals or direct channel accounts; through stocking distributors and healthcare dealers and directly to dental practices and dental laboratories.

Leave a Reply

Zimmer Biomet Holdings Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Zimmer Biomet Holdings Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.